Pages that link to "Q42941680"

The following pages link to Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein (Q42941680):

Displaying 38 items.

• Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination (Q24678848) ‎ (← links)
• The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68 (Q30442838) ‎ (← links)
• Direct identification of tumor-associated peptide antigens. (Q30469600) ‎ (← links)
• Cancer gene and immunotherapy: recent developments (Q33717186) ‎ (← links)
• Human tumor antigens for cancer vaccine development (Q33776127) ‎ (← links)
• Oncogene-linked in situ immunotherapy of pre-B lymphoma arising in E mu/ret transgenic mice (Q36080803) ‎ (← links)
• Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy (Q36239656) ‎ (← links)
• Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide (Q36362759) ‎ (← links)
• Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene (Q36363927) ‎ (← links)
• Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo. (Q36367821) ‎ (← links)
• Tumor antigens discovery: perspectives for cancer therapy (Q36438078) ‎ (← links)
• Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses (Q36470715) ‎ (← links)
• Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. (Q36676048) ‎ (← links)
• A model system for detection and isolation of a tumor cell surface antigen using antibody phage display (Q36858109) ‎ (← links)
• Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen (Q36914397) ‎ (← links)
• Optimizing T-cell receptor gene therapy for hematologic malignancies. (Q38840466) ‎ (← links)
• A novel murine model of allogeneic vaccination against renal cancer (Q39993662) ‎ (← links)
• Tumor escape from immune response by variation in HLA expression and other mechanisms (Q40844521) ‎ (← links)
• The role of the immune system in anti-tumour responses. Potential for drug therapy (Q40931125) ‎ (← links)
• Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein (Q40952603) ‎ (← links)
• Differential binding to frequent HLA-A alleles of p21 RAS derived peptides bearing oncogenic substitutions at position 12 or 13. (Q41100406) ‎ (← links)
• Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses (Q41234424) ‎ (← links)
• Controlled delivery of antigens and adjuvants in vaccine development (Q41264942) ‎ (← links)
• Peptide‐specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K‐ras p21 (Q41304297) ‎ (← links)
• Immunotherapy II: Antigens, receptors and costimulation (Q41349071) ‎ (← links)
• CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation (Q41365421) ‎ (← links)
• Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras. (Q41488786) ‎ (← links)
• T cell defined tumor antigens (Q41642406) ‎ (← links)
• Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity (Q41646149) ‎ (← links)
• Gene therapy in gastroenterology (Q42217358) ‎ (← links)
• Low-level transforming activity of an activated Ras gene under the control of a vaccinia virus p40 promoter is abrogated by truncation of the Ras cDNA. (Q42813389) ‎ (← links)
• Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice. (Q45790647) ‎ (← links)
• T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. (Q52059063) ‎ (← links)
• 38 000 MW antigen-specific major histocompatibility complex class I restricted interferon-gamma-secreting CD8+ T cells in healthy contacts of tuberculosis. (Q52907881) ‎ (← links)
• Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. (Q53471048) ‎ (← links)
• Unconventional cytotoxic T lymphocyte recognition of synthetic peptides corresponding to residues 1—23 of Ras protein (Q57956421) ‎ (← links)
• Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein (Q72995666) ‎ (← links)
• Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection (Q73882460) ‎ (← links)